◆ mixed
Impact
PhasePhase 3
Time to marketIf approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
brilaroxazine Updated Nov 13
What to watch
The immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.
Bull case
- The Phase 3 RECOVER trial met its primary endpoint in October 2023, showing statistically significant efficacy in schizophrenia, and the one-year open-label extension data reinforced consistent, wide-spectrum symptom control.
- Brilaroxazine is a novel serotonin-dopamine stabilizer that may address both positive and negative symptoms of schizophrenia, a key differentiator versus older antipsychotics.
- The FDA granted Orphan Drug Designation for brilaroxazine in pulmonary arterial hypertension (PAH) in April 2026, opening a second potential market.
Bear case
- FDA required a second Phase 3 trial (RECOVER-2) in December 2025, which caused the stock to crash ~50% and delayed any NDA submission by years.
- RECOVER-2 patient enrollment is explicitly contingent on additional financing; with only $17.5M in cash and a ~$3M/quarter burn rate, the company will likely need dilutive equity raises.
- The stock was delisted from Nasdaq to OTCQB in May 2026, severely limiting liquidity and institutional ownership.